{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:33:48Z","timestamp":1771907628924,"version":"3.50.1"},"reference-count":250,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus. The driver for such research was an endeavor to save costs, as both drugs were expensive due to patent protection. Two CYP inhibitors, ketoconazole and diltiazem, have been extensively studied in this context and continue to be prescribed off-label along with the CNI. It has been observed that using ketoconazole reduces the dose requirement of tacrolimus by about 50% and 30% with diltiazem, which is in conformity with their pharmacological actions. Off-label co-prescription of these drugs with CNI is often encountered in low and middle-income countries. The foremost reason cited is economic. This article collates the evidence from the clinical studies that evaluate the PK-boosting effects of CNI and also reviews the gaps in the current evidence base. The current knowledge prevents the transplant community from making meaningful inferences about the risks and benefits of such strategies. Although the PK-boosting strategy can lead to serious adverse events, emerging evidence suggests that it may be advantageous for individuals with high CNI dose requirements. Hence, PK boosting may be an unmet need in the therapeutics of CNI. Nevertheless, there are several unanswered questions surrounding such use, and therefore, this merits testing in well-designed clinical studies. Moreover, drugs with better safer profiles and a history of successful PK boosting may be considered for evaluation with CNI.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001288","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:30Z","timestamp":1736348490000},"page":"118-140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-4685","authenticated-orcid":false,"given":"Smita","family":"Pattanaik","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France;"},{"name":"INSERM UMR-1248 Pharmacologie et Transplantation, Universit\u00e9 Limoges, Limoges, France; and"},{"name":"FHU SUPORT, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/bmj.318.7191.1104","article-title":"Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials","volume":"318","author":"Knoll","year":"1999","journal-title":"BMJ"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0041-1345(00)02301-0","article-title":"Tacrolimus as cornerstone immunosuppressant in kidney transplantation","volume":"33","author":"Berloco","year":"2001","journal-title":"Transpl Proc"},{"key":"R3-20250108","first-page":"1002","article-title":"Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience","volume":"28","author":"Pham","year":"1996","journal-title":"Transpl Proc"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00268-001-0210-5","article-title":"Intestinal and multivisceral transplantation","volume":"26","author":"Kato","year":"2002","journal-title":"World J Surg."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00007890-199901270-00014","article-title":"Long-term results of pancreas transplantation under tacrolimus immunosuppression","volume":"67","author":"Jordan","year":"1999","journal-title":"Transplantation"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1034\/j.1399-0012.2000.140310.x","article-title":"Towards a specific immunosuppression for pancreas and islet grafts","volume":"14","author":"Jindal","year":"2000","journal-title":"Clin Transpl."},{"key":"R7-20250108","first-page":"761","article-title":"Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation","volume":"17","author":"Horning","year":"1998","journal-title":"J Heart Lung Transpl."},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/FTD.0000000000000364","article-title":"A systematic literature review approach to estimate the therapeutic index of selected immunosuppressant drugs after renal transplantation","volume":"39","author":"Ericson","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"1160752","DOI":"10.3389\/frtra.2023.1160752","article-title":"Tacrolimus\u2014why pharmacokinetics matter in the clinic","volume":"2","author":"Henkel","year":"2023","journal-title":"Front Transpl."},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(82)90851-0","article-title":"Ketoconazole, cyclosporin metabolism, and renal transplantation","volume":"2","author":"Ferguson","year":"1982","journal-title":"Lancet"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(82)91545-8","article-title":"Ketoconazole-cyclosporin interaction","volume":"2","author":"Daneshmend","year":"1982","journal-title":"Lancet"},{"key":"R14-20250108","first-page":"555","article-title":"Cyclosporin and ketoconazole, drug interaction or therapeutic association?","volume":"30","author":"Albengres","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jama.1990.03450040018004","article-title":"Cyclosporine-ketoconazole combination offers promise in reducing antirejection therapy costs","volume":"264","author":"Randall","year":"1990","journal-title":"JAMA"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(82)91231-4","article-title":"Ketoconazole and cyclosporin","volume":"2","author":"Dieperink","year":"1982","journal-title":"Lancet."},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(82)91544-6","article-title":"Cyclosporin interaction with ketoconazole and melphalan","volume":"2","author":"Morgenstern","year":"1982","journal-title":"Lancet"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0140-6736(82)91366-6","article-title":"Ketoconazole, cyclosporin, and the kidney","volume":"2","author":"Cunningham","year":"1982","journal-title":"Lancet."},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90398-3","article-title":"Diltiazem and economic use of cyclosporin","volume":"2","author":"Neumayer","year":"1986","journal-title":"Lancet."},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(86)91699-5","article-title":"Influence of diltiazem on cyclosporin clearance","volume":"1","author":"Gri\u00f1o","year":"1986","journal-title":"Lancet"},{"key":"R21-20250108","first-page":"35","article-title":"FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs","volume":"84","author":"Prasad","year":"1994","journal-title":"Res Commun Chem Pathol Pharmacol."},{"key":"R22-20250108","first-page":"121","article-title":"Metabolism of FK 506 in differentially induced rat liver microsomes","volume":"78","author":"Stiff","year":"1992","journal-title":"Res Commun Chem Pathol Pharmacol."},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1996.tb00181.x","article-title":"Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes","volume":"41","author":"Christians","year":"1996","journal-title":"Br J Clin Pharmacol."},{"key":"R24-20250108","first-page":"1017","article-title":"Interaction between FK 506 and diltiazem in an animal model","volume":"28","author":"Regazzi","year":"1996","journal-title":"Transpl Proc"},{"key":"R25-20250108","first-page":"1315","article-title":"Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","article-title":"Tacrolimus oral bioavailability doubles with coadministration of ketoconazole","volume":"62","author":"Floren","year":"1997","journal-title":"Clin Pharmacol Ther."},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1345\/aph.18356","article-title":"Diltiazem increases tacrolimus concentrations","volume":"33","author":"Hebert","year":"1999","journal-title":"Ann Pharmacother."},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-0012.1997.tb00812.x","article-title":"Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients","volume":"11","author":"Katari","year":"1997","journal-title":"Clin Transpl."},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4103\/1319-2442.135033","article-title":"Co-administration of ketoconazole and tacrolimus to kidney transplant recipients: cost minimization and potential metabolic benefits","volume":"25","author":"Elamin","year":"2014","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5527\/wjn.v3.i3.107","article-title":"Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients","volume":"3","author":"Khan","year":"2014","journal-title":"World J Nephrol."},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/ndt\/gfh191","article-title":"Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study","volume":"19","author":"el-Dahshan","year":"2004","journal-title":"Nephrol Dial Transpl."},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5500\/wjt.v10.i11.356","article-title":"Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression","volume":"10","author":"M\u00e9ndez","year":"2020","journal-title":"World J Transpl."},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5500\/wjt.v5.i4.338","article-title":"Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful","volume":"5","author":"Gonz\u00e1lez","year":"2015","journal-title":"World J Transpl."},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/pharmaceutics15041149","article-title":"Pharmacokinetic boosting of kinase inhibitors","volume":"15","author":"Westra","year":"2023","journal-title":"Pharmaceutics"},{"issue":"suppl 1","key":"R35-20250108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bcpt.13623","article-title":"Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions","volume":"130","author":"Eisenmann","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/scipharm86040043","article-title":"Pharmacokinetic enhancers (boosters)\u2014escort for drugs against degrading enzymes and beyond","volume":"86","author":"Krau\u00df","year":"2018","journal-title":"Sci Pharm."},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int J Mol Sci."},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-018-0650-9","article-title":"Complex drug\u2013drug\u2013gene\u2013disease interactions involving cytochromes P450: systematic review of published case reports and clinical perspectives","volume":"57","author":"Storelli","year":"2018","journal-title":"Clin Pharmacokin"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype","volume":"50","author":"Waring","year":"2020","journal-title":"Xenobiotica"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1389200218666170531112038","article-title":"Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery","volume":"18","author":"Lolodi","year":"2017","journal-title":"Curr Drug Metab."},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bcp.15590","article-title":"Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: a proof-of-concept case study","volume":"89","author":"De la Garza-Salazar","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther."},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"1759720X221142277","DOI":"10.1177\/1759720X221142277","article-title":"Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)","volume":"14","author":"van der Togt","year":"2022","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2022.07.012","article-title":"Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: the OSIBOOST trial","volume":"171","author":"van Veelen","year":"2022","journal-title":"Lung Cancer"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/ejh.13418","article-title":"Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): enabling dose reduction and relief of treatment burden","volume":"105","author":"Boons","year":"2020","journal-title":"Eur J Haematol."},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/cts.12716","article-title":"Itraconazole increases ibrutinib exposure 10-fold and reduces interindividual variation\u2014a potentially beneficial drug-drug interaction","volume":"13","author":"Tapaninen","year":"2020","journal-title":"Clin Transl Sci."},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11095-022-03244-8","article-title":"Ritonavir-boosted exposure of kinase inhibitors: an open label, cross-over pharmacokinetic proof-of-concept trial with erlotinib","volume":"39","author":"Boosman","year":"2022","journal-title":"Pharm Res."},{"key":"R54-20250108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12921","article-title":"Pharmacoenhancement of low crizotinib plasma concentrations in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer using the CYP3A inhibitor cobicistat","volume":"14","author":"Hohmann","year":"2021","journal-title":"Clin Transl Sci."},{"key":"R55-20250108","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/0284186X.2017.1311024","article-title":"Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal","volume":"56","author":"Lubberman","year":"2017","journal-title":"Acta Oncol."},{"key":"R57-20250108","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J Pharm Pharmacol."},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/21556660.2013.785413","article-title":"Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers","volume":"2","author":"Teng","year":"2013","journal-title":"J Drug Assess."},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/jcph.1622","article-title":"Proposal of a safe and effective study design for CYP3A-mediated drug-drug interactions","volume":"60","author":"Rohr","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"R60-20250108","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","article-title":"Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome","volume":"172","author":"Daniel","year":"2015","journal-title":"Eur J Endocrinol."},{"key":"R63-20250108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cpdd.652","article-title":"Ketoconazole and liver injury: a five-year update","volume":"8","author":"Greenblatt","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R64-20250108","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jcph.795","article-title":"No increased risk of ketoconazole toxicity in drug-drug interaction studies","volume":"56","author":"Outeiro","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"R65-20250108","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/jcph.400","article-title":"Liver injury associated with ketoconazole: review of the published evidence","volume":"54","author":"Greenblatt","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"R66-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpdd.100","article-title":"The ketoconazole legacy","volume":"3","author":"Greenblatt","year":"2014","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R67-20250108","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/jcph.711","article-title":"Ketoconazole-associated liver injury in drug-drug interaction studies in healthy volunteers","volume":"56","author":"Banankhah","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"R69-20250108","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation","volume":"290","author":"Jones","year":"1999","journal-title":"J Pharmacol Exp Ther."},{"key":"R70-20250108","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R71-20250108","first-page":"749","article-title":"Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study","volume":"13","author":"Lu","year":"2016","journal-title":"J Geriatr Cardiol."},{"key":"R72-20250108","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/01.CCM.0000278916.04569.23","article-title":"Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil","volume":"35","author":"Levine","year":"2007","journal-title":"Crit Care Med."},{"key":"R73-20250108","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(87)92710-3","article-title":"Verapamil inhibits cyclosporin metabolism","volume":"1","author":"Lindholm","year":"1987","journal-title":"Lancet"},{"key":"R74-20250108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5694\/j.1326-5377.1992.tb137177.x","article-title":"Cyclosporin and calcium channel blockers: an exploitable drug interaction?","volume":"157","author":"Leibbrandt","year":"1992","journal-title":"Med J Aust."},{"key":"R75-20250108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/08860229009087123","article-title":"The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients","volume":"12","author":"Howard","year":"1990","journal-title":"Ren Fail."},{"key":"R76-20250108","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00856514","article-title":"The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients","volume":"8","author":"Crocker","year":"1994","journal-title":"Pediatr Nephrol."},{"key":"R77-20250108","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00003088-199732050-00002","article-title":"The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations","volume":"32","author":"Jones","year":"1997","journal-title":"Clin Pharmacokinet."},{"key":"R78-20250108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0140-6736(87)91412-7","article-title":"Itraconazole and cyclosporin nephrotoxicity","volume":"330","author":"Nov\u00e1kov\u00e1","year":"1987","journal-title":"Lancet."},{"key":"R79-20250108","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(87)91232-3","article-title":"Time course of cyclosporin\/itraconazole interaction","volume":"2","author":"Trenk","year":"1987","journal-title":"Lancet"},{"key":"R80-20250108","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7326\/0003-4819-113-4-327","article-title":"Cyclosporine and itraconazole interaction in heart and lung transplant recipients","volume":"113","author":"Kramer","year":"1990","journal-title":"Ann Intern Med."},{"key":"R81-20250108","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(87)90873-7","article-title":"Interaction of cyclosporin and itraconazole","volume":"2","author":"Kwan","year":"1987","journal-title":"Lancet"},{"key":"R82-20250108","first-page":"84","article-title":"Use of cyclosporine and ketoconazole without nephrotoxicity in two heart transplant recipients","volume":"6","author":"Schroeder","year":"1987","journal-title":"J Heart Transpl."},{"key":"R83-20250108","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(89)91802-3","article-title":"Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients","volume":"2","author":"First","year":"1989","journal-title":"Lancet"},{"key":"R84-20250108","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007890-199102000-00018","article-title":"Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients","volume":"51","author":"First","year":"1991","journal-title":"Transplantation"},{"key":"R85-20250108","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00856546","article-title":"Pediatric clinical use of the ketoconazole\/cyclosporin interaction","volume":"8","author":"Berkovitch","year":"1994","journal-title":"Pediatr Nephrol."},{"key":"R86-20250108","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00007890-199403270-00021","article-title":"A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome","volume":"57","author":"Patton","year":"1994","journal-title":"Transplantation"},{"key":"R87-20250108","first-page":"1038","article-title":"Cardiac transplantation: economizing cyclosporin A by including ketoconazole in the immunosuppressive schedule","volume":"119","author":"Becerra","year":"1991","journal-title":"Rev Med Chil"},{"key":"R88-20250108","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0971-4065.120338","article-title":"Cyclosporine\/ketoconazole reduces treatment costs for nephrotic syndrome","volume":"23","author":"Iyengar","year":"2013","journal-title":"Indian J Nephrol."},{"key":"R89-20250108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00228-005-0064-0","article-title":"Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome","volume":"62","author":"El-Husseini","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"R90-20250108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000078395","article-title":"Effect of concomitant administration of cyclosporine and ketoconazole in children with focal segmental glomerulosclerosis","volume":"24","author":"El-Husseini","year":"2004","journal-title":"Am J Nephrol."},{"key":"R91-20250108","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/01.TP.0000122343.51904.C3","article-title":"Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience","volume":"77","author":"Carbajal","year":"2004","journal-title":"Transplantation"},{"key":"R92-20250108","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00007890-199305000-00009","article-title":"Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial","volume":"55","author":"First","year":"1993","journal-title":"Transplantation"},{"key":"R93-20250108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJM199509073331004","article-title":"Ketoconazole to reduce the need for cyclosporine after cardiac transplantation","volume":"333","author":"Keogh","year":"1995","journal-title":"N Engl J Med."},{"key":"R94-20250108","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000168892","article-title":"Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study","volume":"15","author":"Sobh","year":"1995","journal-title":"Am J Nephrol."},{"key":"R95-20250108","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/01.TP.0000121133.84763.26","article-title":"A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up","volume":"77","author":"El-Agroudy","year":"2004","journal-title":"Transplantation"},{"key":"R96-20250108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007890-199602270-00004","article-title":"Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole","volume":"61","author":"Moore","year":"1996","journal-title":"Transplantation"},{"key":"R97-20250108","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1365-2125.2003.01908.x","article-title":"Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin","volume":"56","author":"Kumana","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R98-20250108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/lt.500010609","article-title":"Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine","volume":"1","author":"Al Edreesi","year":"1995","journal-title":"Liver Transpl Surg"},{"key":"R99-20250108","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1046\/j.1523-1755.2002.00386.x","article-title":"Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients","volume":"61","author":"McDonald","year":"2002","journal-title":"Kidney Int."},{"issue":"suppl 2","key":"R100-20250108","first-page":"S235","article-title":"Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four year follow-up study","volume":"89","author":"Ingsathit","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"R101-20250108","doi-asserted-by":"crossref","first-page":"e31166","DOI":"10.1097\/MD.0000000000031166","article-title":"Diltiazem as a cyclosporine A-sparing agent in heart transplantation: benefits beyond dose reduction","volume":"101","author":"Alyaydin","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R102-20250108","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(86)91086-X","article-title":"Cyclosporin-diltiazem interaction","volume":"1","author":"Pochet","year":"1986","journal-title":"Lancet."},{"key":"R103-20250108","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000167487","article-title":"Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study","volume":"7","author":"Wagner","year":"1987","journal-title":"Am J Nephrol."},{"key":"R104-20250108","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1055\/s-2008-1068635","article-title":"Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study","volume":"111","author":"Wagner","year":"1986","journal-title":"Dtsch Med Wochenschr"},{"key":"R105-20250108","first-page":"1353","article-title":"Influence of the calcium antagonist diltiazem on delayed graft function in cadaveric kidney transplantation: results of a 6-month follow-up","volume":"19","author":"Wagner","year":"1987","journal-title":"Transpl Proc"},{"issue":"suppl 10","key":"R106-20250108","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1097\/00005344-198710100-00058","article-title":"Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials","volume":"10","author":"Neumayer","year":"1987","journal-title":"J Cardiovasc Pharmacol."},{"key":"R107-20250108","first-page":"572","article-title":"Effect of the calcium channel blocker diltiazem on cyclosporine A blood levels and dose requirements","volume":"20","author":"Kohlhaw","year":"1988","journal-title":"Transpl Proc"},{"key":"R108-20250108","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(91)90587-N","article-title":"Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs","volume":"90","author":"Bourge","year":"1991","journal-title":"Am J Med."},{"key":"R109-20250108","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/j.1875-9114.1994.tb02839.x","article-title":"Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients","volume":"14","author":"Smith","year":"1994","journal-title":"Pharmacotherapy"},{"key":"R110-20250108","first-page":"1","article-title":"Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation","volume":"11","author":"Valantine","year":"1992","journal-title":"J Heart Lung Transpl."},{"key":"R111-20250108","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/00007890-199312000-00051","article-title":"The immunosuppressive qualities of calcium channel blockers","volume":"56","author":"Alivizatos","year":"1993","journal-title":"Transplantation"},{"key":"R112-20250108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00007890-199108000-00018","article-title":"Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients","volume":"52","author":"Kunzendorf","year":"1991","journal-title":"Transplantation"},{"key":"R113-20250108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1365-2125.1997.t01-1-00616.x","article-title":"Diltiazem-cyclosporin pharmacokinetic interaction\u2014dose-response relationship","volume":"44","author":"Jones","year":"1997","journal-title":"Br J Clin Pharmacol."},{"key":"R114-20250108","first-page":"55","article-title":"Formulation of diltiazem affects cyclosporin-sparing activity","volume":"52","author":"Jones","year":"1997","journal-title":"Eur J Clin Pharmacol."},{"key":"R115-20250108","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007691-199808000-00001","article-title":"Diltiazem disposition and metabolism in recipients of renal transplants","volume":"20","author":"Morris","year":"1998","journal-title":"Ther Drug Monit."},{"issue":"suppl 6","key":"R116-20250108","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00005344-199006166-00004","article-title":"Calcium channel blockers for kidney protection","volume":"16","author":"Frei","year":"1990","journal-title":"J Cardiovasc Pharmacol."},{"key":"R117-20250108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2125.1996.tb00062.x","article-title":"Diltiazem does not always increase blood cyclosporin concentration","volume":"42","author":"Jones","year":"1996","journal-title":"Br J Clin Pharmacol."},{"key":"R118-20250108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0272-6386(99)70304-5","article-title":"Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil","volume":"33","author":"Jacob","year":"1999","journal-title":"Am J Kidney Dis."},{"key":"R119-20250108","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/106002809402801101","article-title":"Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients","volume":"28","author":"Sketris","year":"1994","journal-title":"Ann Pharmacother."},{"key":"R120-20250108","first-page":"575","article-title":"Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil","volume":"48","author":"Dawidson","year":"1989","journal-title":"Transplantation"},{"key":"R121-20250108","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1681\/ASN.V25983","article-title":"Verapamil improves the outcome after cadaver renal transplantation","volume":"2","author":"Dawidson","year":"1991","journal-title":"J Am Soc Nephrol."},{"key":"R122-20250108","first-page":"705","article-title":"Increased cyclosporine blood concentrations due to verapamil administration","volume":"22","author":"Maggio","year":"1988","journal-title":"Drug Intell Clin Pharm."},{"key":"R123-20250108","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","article-title":"The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients","volume":"71","author":"Tuteja","year":"2001","journal-title":"Transplantation"},{"key":"R124-20250108","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0041-1345(03)00450-0","article-title":"Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects","volume":"35","author":"Soltero","year":"2003","journal-title":"Transpl Proc"},{"key":"R125-20250108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000094133","article-title":"Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study","volume":"26","author":"El-Dahshan","year":"2006","journal-title":"Am J Nephrol."},{"key":"R126-20250108","first-page":"1","article-title":"Combination of ketoconazole and tacrolimus increases the risk of kidney transplant rejection in African Americans","volume":"1","author":"Zhang","year":"2018","journal-title":"J Surg Forecast."},{"key":"R127-20250108","doi-asserted-by":"crossref","first-page":"14247","DOI":"10.1038\/s41598-022-18552-7","article-title":"The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial","volume":"12","author":"Susomboon","year":"2022","journal-title":"Sci Rep."},{"key":"R128-20250108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2710.2004.00578.x","article-title":"Diltiazem use in tacrolimus-treated renal transplant recipients","volume":"29","author":"Kothari","year":"2004","journal-title":"J Clin Pharm Ther."},{"key":"R129-20250108","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/tpj.2010.42","article-title":"Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective","volume":"11","author":"Li","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"R130-20250108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00228-018-2604-4","article-title":"Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis","volume":"75","author":"Sun","year":"2019","journal-title":"Eur J Clin Pharmacol."},{"key":"R131-20250108","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00228-020-02977-y","article-title":"Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms","volume":"77","author":"Wang","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"R132-20250108","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FTD.0000000000000850","article-title":"High intrapatient variability in tacrolimus exposure calculated over a long period is associated with de novo donor-specific antibody development and\/or late rejection in thai kidney transplant patients receiving concomitant CYP3A4\/5 inhibitors","volume":"43","author":"Larpparisuth","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R133-20250108","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-200241050-00005","article-title":"Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients","volume":"41","author":"Jones","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R134-20250108","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.transproceed.2018.04.024","article-title":"Dose-response relationship between diltiazem and tacrolimus and its safety in renal transplant recipients","volume":"50","author":"Choong","year":"2018","journal-title":"Transpl Proc"},{"key":"R135-20250108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jcpt.13043","article-title":"Efficacy and safety of ketoconazole combined with calmodulin inhibitor in solid organ transplantation: a systematic review and meta-analysis","volume":"45","author":"Xue","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"R136-20250108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FPC.0b013e32832bd085","article-title":"CYP3A5*1\/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole","volume":"19","author":"Chandel","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R137-20250108","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1600-6143.2004.00435.x","article-title":"The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation","volume":"4","author":"MacPhee","year":"2004","journal-title":"Am J Transpl."},{"key":"R138-20250108","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","article-title":"CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation","volume":"26","author":"Glowacki","year":"2011","journal-title":"Nephrol Dial Transpl."},{"key":"R139-20250108","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1432-2277.2012.01446.x","article-title":"Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation","volume":"25","author":"Gervasini","year":"2012","journal-title":"Transpl Int."},{"key":"R140-20250108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00228-015-1990-0","article-title":"Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation","volume":"72","author":"Yaowakulpatana","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R141-20250108","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/pgs-2016-0146","article-title":"Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes","volume":"18","author":"Flahault","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R142-20250108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","article-title":"The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis","volume":"22","author":"Terrazzino","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R143-20250108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/tpj.2014.38","article-title":"Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies","volume":"15","author":"Rojas","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"R144-20250108","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000528109","article-title":"CYP3A5 expressor genotype of the transplanted kidney increases the risk of preterm graft loss and acute rejection","volume":"147","author":"Warzyszynska","year":"2023","journal-title":"Nephron"},{"key":"R146-20250108","doi-asserted-by":"crossref","first-page":"e67812","DOI":"10.1371\/journal.pone.0067812","article-title":"Kidney transplantation is associated with catastrophic out of pocket expenditure in India","volume":"8","author":"Ramachandran","year":"2013","journal-title":"PLoS One"},{"key":"R147-20250108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.tp.0000269797.41202.79","article-title":"The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients","volume":"84","author":"Rodrigue","year":"2007","journal-title":"Transplantation"},{"key":"R148-20250108","doi-asserted-by":"crossref","first-page":"e1439","DOI":"10.1097\/TXD.0000000000001439","article-title":"Does the tacrolimus trough level adequately predict drug exposure in patients requiring a high tacrolimus dose?","volume":"9","author":"Haverals","year":"2023","journal-title":"Transpl Direct"},{"key":"R149-20250108","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/TP.0000000000004405","article-title":"Can the area under the curve\/trough level ratio be used to optimize tacrolimus individual dose adjustment?","volume":"107","author":"Woillard","year":"2023","journal-title":"Transplantation"},{"key":"R150-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R151-20250108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"R152-20250108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138920007779815986","article-title":"Transcriptional regulation and expression of CYP3A4 in hepatocytes","volume":"8","author":"Mart\u00ednez-Jim\u00e9nez","year":"2007","journal-title":"Curr Drug Metab."},{"key":"R153-20250108","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int."},{"key":"R154-20250108","first-page":"675301","article-title":"Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study","volume":"2014","author":"Tielen","year":"2014","journal-title":"J Transpl."},{"key":"R155-20250108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12882-017-0517-6","article-title":"Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation","volume":"18","author":"Scheel","year":"2017","journal-title":"BMC Nephrol."},{"key":"R156-20250108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R157-20250108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R158-20250108","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/14622416.8.7.835","article-title":"Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update","volume":"8","author":"Anglicheau","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R159-20250108","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2125.1990.tb03796.x","article-title":"A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation","volume":"30","author":"Lindholm","year":"1990","journal-title":"Br J Clin Pharmacol."},{"key":"R160-20250108","first-page":"971","article-title":"Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone","volume":"21","author":"Iwasaki","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R161-20250108","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0163-7258(93)90059-M","article-title":"Cyclosporin metabolism in transplant patients","volume":"57","author":"Christians","year":"1993","journal-title":"Pharmacol Ther."},{"key":"R162-20250108","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab Pharmacokinet."},{"key":"R163-20250108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clpt.2003.12.009","article-title":"Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients","volume":"75","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R164-20250108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0041-1345(98)01633-9","article-title":"Low systemic exposure to tacrolimus correlates with acute rejection","volume":"31","author":"Undre","year":"1999","journal-title":"Transpl Proc"},{"key":"R165-20250108","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","article-title":"Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure","volume":"35","author":"Saint-Marcoux","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R166-20250108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FTD.0000000000000503","article-title":"Pharmacokinetic therapeutic drug monitoring of advagraf in more than 500 adult renal transplant patients, using an expert system online","volume":"40","author":"Marquet","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R167-20250108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bcp.12763","article-title":"Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies","volume":"81","author":"Graudins","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R168-20250108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-97-3-370","article-title":"Ketoconazole blocks adrenal steroid synthesis","volume":"97","author":"Pont","year":"1982","journal-title":"Ann Intern Med."},{"key":"R169-20250108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(85)92073-2","article-title":"Ketoconazole and adrenocortical secretion","volume":"1","author":"Dandona","year":"1985","journal-title":"Lancet."},{"key":"R170-20250108","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1210\/jcem-65-3-551","article-title":"Kinetic analysis of inhibition of human adrenal steroidogenesis by ketoconazole","volume":"65","author":"Couch","year":"1987","journal-title":"J Clin Endocrinol Metab."},{"key":"R171-20250108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.1989.42","article-title":"Impact of ketoconazole on the metabolism of prednisolone","volume":"45","author":"Z\u00fcrcher","year":"1989","journal-title":"Clin Pharmacol Ther."},{"key":"R172-20250108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/152692480401400303","article-title":"Nonprescription analgesics and their use in solid-organ transplantation: a review","volume":"14","author":"Gabardi","year":"2004","journal-title":"Prog Transpl."},{"key":"R173-20250108","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/157340309788970397","article-title":"Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance","volume":"5","author":"Cubeddu","year":"2009","journal-title":"Curr Cardiol Rev."},{"key":"R174-20250108","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0306-3623(96)00081-X","article-title":"The P-glycoprotein multidrug transporter","volume":"27","author":"Fardel","year":"1996","journal-title":"Gen Pharmacol."},{"key":"R175-20250108","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020679","article-title":"A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators","volume":"15","author":"Marok","year":"2023","journal-title":"Pharmaceutics"},{"key":"R176-20250108","doi-asserted-by":"crossref","first-page":"118518","DOI":"10.1016\/j.lfs.2020.118518","article-title":"Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein","volume":"262","author":"El-Mahdy","year":"2020","journal-title":"Life Sci."},{"key":"R177-20250108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00280138","article-title":"Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2","volume":"42","author":"Fuhr","year":"1992","journal-title":"Eur J Clin Pharmacol."},{"key":"R178-20250108","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","article-title":"Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)","volume":"96","author":"Gupta","year":"2007","journal-title":"J Pharm Sci."},{"key":"R179-20250108","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol."},{"key":"R180-20250108","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2125.2001.01386.x","article-title":"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes","volume":"51","author":"Yeo","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R181-20250108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"R182-20250108","first-page":"295","article-title":"Rhabdomyolysis induced by simvastatin and ketoconazole treatment","volume":"22","author":"Gilad","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"R183-20250108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0022-5347(05)63967-5","article-title":"Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer","volume":"169","author":"Itakura","year":"2003","journal-title":"J Urol."},{"key":"R184-20250108","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/15563650701779703","article-title":"Colchicine-induced toxicity in a heart transplant patient with chronic renal failure","volume":"46","author":"Eleftheriou","year":"2008","journal-title":"Clin Toxicol (Phila)"},{"key":"R185-20250108","first-page":"13","article-title":"Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole","volume":"3","author":"Patel","year":"2011","journal-title":"Clin Pharmacol."},{"key":"R186-20250108","doi-asserted-by":"crossref","first-page":"e203593","DOI":"10.1001\/jamanetworkopen.2020.3593","article-title":"Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function","volume":"3","author":"Pham","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R187-20250108","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R188-20250108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/pharmaceutics11030133","article-title":"Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of rivaroxaban","volume":"11","author":"Kim","year":"2019","journal-title":"Pharmaceutics"},{"key":"R189-20250108","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"key":"R190-20250108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf."},{"key":"R191-20250108","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.38.2.326","article-title":"In vivo interaction of ketoconazole and sucralfate in healthy volunteers","volume":"38","author":"Carver","year":"1994","journal-title":"Antimicrob Agents Chemother."},{"key":"R192-20250108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/11531320-000000000-00000","article-title":"Drug-drug interaction profiles of proton pump inhibitors","volume":"49","author":"Ogawa","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"R193-20250108","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transpl."},{"key":"R194-20250108","first-page":"1554","article-title":"Decreased cyclosporine concentrations with the addition of an H2-receptor antagonist in a patient on ketoconazole","volume":"56","author":"Karlix","year":"1993","journal-title":"Transplantation"},{"key":"R195-20250108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.18388\/abp.1995_4904","article-title":"Mechanisms of resistance to azole antifungals","volume":"42","author":"Marichal","year":"1995","journal-title":"Acta Biochim Pol."},{"key":"R196-20250108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0732-8893(98)00107-2","article-title":"Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure","volume":"32","author":"Milan","year":"1998","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R197-20250108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/35.1.103","article-title":"Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis","volume":"35","author":"Johnson","year":"1995","journal-title":"J Antimicrob Chemother."},{"key":"R198-20250108","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/jhh.2008.157","article-title":"Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin\u2013angiotensin system","volume":"23","author":"de la Sierra","year":"2009","journal-title":"J Hum Hypertens"},{"key":"R199-20250108","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate\u2014a meta-analysis of randomized trials","volume":"29","author":"Makani","year":"2011","journal-title":"J Hypertens."},{"key":"R200-20250108","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1540-8159.2012.03410.x","article-title":"Management of patients with drug-induced atrioventricular block","volume":"35","author":"Osmonov","year":"2012","journal-title":"Pacing Clin Electrophysiol."},{"key":"R201-20250108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00044011-200323040-00009","article-title":"Fatal cardiogenic shock and liver failure induced by verapamil in a thyrotoxic patient","volume":"23","author":"Margolin","year":"2003","journal-title":"Clin Drug Investig."},{"key":"R202-20250108","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1001\/archinte.1991.00400100143024","article-title":"Acute toxic effects of sustained-release verapamil in chronic renal failure","volume":"151","author":"Pritza","year":"1991","journal-title":"Arch Intern Med."},{"key":"R203-20250108","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000140769.31248.79","article-title":"Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single center experience","volume":"79","author":"Carbajal","year":"2005","journal-title":"Transplantation"},{"key":"R204-20250108","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamainternmed.2024.1836","article-title":"Severe acute liver injury after hepatotoxic medication initiation in real-world data","volume":"184","author":"Torgersen","year":"2024","journal-title":"JAMA Intern Med."},{"key":"R205-20250108","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475415574970","article-title":"The rise and fall of oral ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J Cutan Med Surg."},{"key":"R206-20250108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14740338.2015.983071","article-title":"Drug safety assessment of oral formulations of ketoconazole","volume":"14","author":"Gupta","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"R207-20250108","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","article-title":"Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases","volume":"86","author":"Lewis","year":"1984","journal-title":"Gastroenterology"},{"key":"R208-20250108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1089-3261(05)70097-0","article-title":"Drug-induced liver disease","volume":"4","author":"Zimmerman","year":"2000","journal-title":"Clin Liver Dis."},{"key":"R209-20250108","first-page":"217","article-title":"Evaluation of ketoconazole","volume":"1","author":"Sohn","year":"1982","journal-title":"Clin Pharm."},{"key":"R210-20250108","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing's disease: adrenal steroidogenesis inhibitors","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"R211-20250108","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.19.6.1073","article-title":"Gynecomastia with ketoconazole","volume":"19","author":"DeFelice","year":"1981","journal-title":"Antimicrob Agents Chemother."},{"key":"R212-20250108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in Cushing's syndrome: experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R213-20250108","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/jcem-63-3-766","article-title":"Ketoconazole-induced reduction in serum 1, 25-dihydroxyvitamin D","volume":"63","author":"Glass","year":"1986","journal-title":"J Clin Endocrinol Metab."},{"key":"R214-20250108","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0002-9343(86)90816-8","article-title":"Inhibition of cholesterol synthesis by ketoconazole","volume":"80","author":"Kraemer","year":"1986","journal-title":"Am J Med."},{"key":"R215-20250108","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","article-title":"Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes","volume":"71","author":"Loose","year":"1983","journal-title":"J Clin Invest."},{"key":"R216-20250108","first-page":"468","article-title":"Cyclosporine-ketoconazole: a potentially dangerous drug-drug interaction","volume":"5","author":"Shepard","year":"1986","journal-title":"Clin Pharm."},{"key":"R217-20250108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1399-0012.1997.tb01050.x","article-title":"Unexpectedly low immunocompetence in transplant patients on ketoconazole","volume":"11","author":"Watanabe","year":"1997","journal-title":"Clin Transpl."},{"key":"R218-20250108","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1445-5994.1989.tb00264.x","article-title":"The ketoconazole-cyclosporin interaction in an elderly renal transplant patient","volume":"19","author":"Charles","year":"1989","journal-title":"Aust N Z J Med."},{"key":"R219-20250108","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-4362.1988.tb01276.x","article-title":"Severe gingival hyperplasia following cyclosporin and ketoconazole therapy","volume":"27","author":"Veraldi","year":"1988","journal-title":"Int J Dermatol."},{"key":"R220-20250108","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/bmj.287.6406.1673","article-title":"Anaphylactic reactions to ketoconazole","volume":"287","author":"van Dijke","year":"1983","journal-title":"Br Med J (Clin Res Ed)."},{"key":"R221-20250108","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1345\/aph.1E465","article-title":"Refractory anaphylactic shock associated with ketoconazole treatment","volume":"39","author":"Liu","year":"2005","journal-title":"Ann Pharmacother."},{"key":"R222-20250108","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/tri.14127","article-title":"Therapeutic education as a tool to improve patient-reported and clinical outcomes after renal transplantation: results of the EPHEGREN multicenter retrospective cohort study","volume":"34","author":"Villeneuve","year":"2021","journal-title":"Transpl Int."},{"key":"R223-20250108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/tri.12312","article-title":"Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss Transplant Cohort Study","volume":"27","author":"De Geest","year":"2014","journal-title":"Transpl Int."},{"key":"R224-20250108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.TP.0000110408.83054.88","article-title":"Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"key":"R225-20250108","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/lt.22294","article-title":"Adherence in liver transplant recipients","volume":"17","author":"Burra","year":"2011","journal-title":"Liver Transpl."},{"key":"R226-20250108","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10620-012-2412-0","article-title":"Non-adherence and graft failure in adult liver transplant recipients","volume":"58","author":"Lieber","year":"2013","journal-title":"Dig Dis Sci."},{"key":"R227-20250108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"},{"key":"R228-20250108","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13142","article-title":"Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf\u2122) in kidney transplant patients in Germany: a multicenter, noninterventional study","volume":"32","author":"Lehner","year":"2018","journal-title":"Clin Transpl."},{"key":"R229-20250108","doi-asserted-by":"crossref","first-page":"e13844","DOI":"10.1111\/ctr.13844","article-title":"Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: results of a randomized controlled pilot study","volume":"34","author":"Taber","year":"2020","journal-title":"Clin Transpl."},{"key":"R230-20250108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.healun.2021.02.017","article-title":"Once daily tacrolimus conversion in lung transplantation: a prospective study on safety and medication adherence","volume":"40","author":"Godinas","year":"2021","journal-title":"J Heart Lung Transpl."},{"key":"R231-20250108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0140-6736(90)90573-N","article-title":"Concomitant cyclosporin and ketoconazole","volume":"335","author":"Frey","year":"1990","journal-title":"Lancet."},{"key":"R232-20250108","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1445-5994.1996.tb00623.x","article-title":"Survey of cyclosporin-sparing agent use in Australasian transplant centres","volume":"26","author":"Jones","year":"1996","journal-title":"Aust N Z J Med."},{"key":"R233-20250108","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R234-20250108","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1097\/QAD.0000000000000800","article-title":"Twenty years of boosting antiretroviral agents: where are we today?","volume":"29","author":"Boffito","year":"2015","journal-title":"Aids"},{"key":"R235-20250108","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother."},{"key":"R236-20250108","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-1755.2004.00772.x","article-title":"Antiretroviral and immunosuppressive drug-drug interactions: an update","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int."},{"key":"R237-20250108","doi-asserted-by":"crossref","first-page":"e0011122","DOI":"10.1128\/cmr.00111-22","article-title":"Overcoming barriers and stigma: new frontiers in solid organ transplantation for people with HIV","volume":"37","author":"Storm","year":"2024","journal-title":"Clin Microbiol Rev."},{"key":"R238-20250108","doi-asserted-by":"crossref","first-page":"e12992","DOI":"10.1111\/tid.12992","article-title":"Impact of antiretroviral regimen on renal transplant outcomes in HIV-infected recipients","volume":"20","author":"Sparkes","year":"2018","journal-title":"Transpl Infect Dis."},{"key":"R239-20250108","doi-asserted-by":"crossref","first-page":"e13534","DOI":"10.1111\/ctr.13534","article-title":"Higher rates of rejection in HIV-infected kidney transplant recipients on ritonavir-boosted protease inhibitors: 3-year follow-up study","volume":"33","author":"Rollins","year":"2019","journal-title":"Clin Transpl."},{"key":"R240-20250108","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.ekir.2022.06.013","article-title":"Retrospective Review of ART regimens in HIV-positive to HIV-positive kidney transplant recipients","volume":"7","author":"Barday","year":"2022","journal-title":"Kidney Int Rep."},{"key":"R241-20250108","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.transproceed.2020.10.003","article-title":"Impact of protease inhibitor-based antiretroviral therapy on tacrolimus intrapatient variability in HIV-positive kidney transplant recipients","volume":"53","author":"Cooper","year":"2021","journal-title":"Transpl Proc"},{"key":"R242-20250108","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants","volume":"22","author":"Lange","year":"2022","journal-title":"Am J Transpl."},{"key":"R243-20250108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R244-20250108","doi-asserted-by":"crossref","first-page":"12360","DOI":"10.3389\/ti.2024.12360","article-title":"Adaptative strategy of immunosuppressive drugs dosage adjustments when combined with nirmatrelvir\/ritonavir in solid organ transplant recipients with COVID-19","volume":"37","author":"Boland","year":"2024","journal-title":"Transpl Int."},{"key":"R246-20250108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0378-8741(81)90037-4","article-title":"Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs","volume":"4","author":"Atal","year":"1981","journal-title":"J Ethnopharmacol"},{"key":"R247-20250108","first-page":"258","article-title":"Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism","volume":"232","author":"Atal","year":"1985","journal-title":"J Pharmacol Exp Ther."},{"key":"R248-20250108","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/jpet.102.034728","article-title":"Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4","volume":"302","author":"Bhardwaj","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"R249-20250108","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1078\/0944-7113-00114","article-title":"Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics","volume":"9","author":"Khajuria","year":"2002","journal-title":"Phytomedicine"},{"key":"R250-20250108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1124\/dmd.119.088955","article-title":"Piperine is a mechanism-based inactivator of CYP3A","volume":"48","author":"Cui","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"R251-20250108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/2949681015666220804103005","article-title":"Mechanism-based inhibition of CYP3A subfamilies by macrolide antibiotics and piperine","volume":"15","author":"Niwa","year":"2022","journal-title":"Drug Metab Bioanal Lett."},{"key":"R252-20250108","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ptr.1937","article-title":"Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy","volume":"20","author":"Pattanaik","year":"2006","journal-title":"Phytother Res."},{"key":"R253-20250108","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-2006-962814","article-title":"The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers","volume":"53","author":"Bano","year":"1987","journal-title":"Planta Med."},{"key":"R254-20250108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF03226378","article-title":"Piperine in food: interference in the pharmacokinetics of phenytoin","volume":"26","author":"Velpandian","year":"2001","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R255-20250108","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ptr.2676","article-title":"Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients","volume":"23","author":"Pattanaik","year":"2009","journal-title":"Phytother Res."},{"key":"R256-20250108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF00314996","article-title":"Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers","volume":"41","author":"Bano","year":"1991","journal-title":"Eur J Clin Pharmacol."},{"key":"R257-20250108","first-page":"223","article-title":"Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis","volume":"33","author":"Zutshi","year":"1985","journal-title":"J Assoc Physicians India"},{"key":"R258-20250108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00126839-200708060-00006","article-title":"Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions","volume":"8","author":"Kasibhatta","year":"2007","journal-title":"Drugs R D"},{"key":"R259-20250108","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2008-2231-22-8","article-title":"The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism","volume":"22","author":"Rezaee","year":"2014","journal-title":"Daru"},{"key":"R260-20250108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s43088-022-00196-1","article-title":"Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: evidence from clinical trials","volume":"11","author":"Tripathi","year":"2022","journal-title":"Beni Suef Univ J Basic Appl Sci."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:03:02Z","timestamp":1736348582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":250,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001288","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"2024-09-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}